Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer
Clinical Breast Cancer · 2023
DOI: 10.1016/j.clbc.2023.06.014 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Clinical Breast Cancer, 2023. Verfasst von Saya Jacob und 6 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Breast Neoplasms, Quinolines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Puma Biotechnology Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
- Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA. Electronic address: Jo.chien@ucsf.edu.
Förderung
- Puma Biotechnology Inc
Zitieren
APA
Jacob, S., Johnson, M., Roque, B., Quintal, L., Rugo, H. S., Melisko, M., & Chien, A. J. (2023). Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2023.06.014
Vancouver
Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, et al. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer. Clinical Breast Cancer. 2023. doi:10.1016/j.clbc.2023.06.014
BibTeX
@article{Jacob2023,
author = {Jacob, Saya and Johnson, MacKenzie and Roque, Brianna and Quintal, Laura and Rugo, Hope S and Melisko, Michelle and Chien, Amy Jo},
title = {Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2023},
doi = {10.1016/j.clbc.2023.06.014}
}
EUVIMED